scholarly journals Ghrelin mitigatesβ-cell mass loss during insulitis in an animal model of autoimmune diabetes mellitus, the BioBreeding/Worcester rat

2016 ◽  
Vol 33 (1) ◽  
pp. e2813 ◽  
Author(s):  
Gloria Baena-Nieto ◽  
Isabel M. Lomas-Romero ◽  
Rosa M. Mateos ◽  
Noelia Leal-Cosme ◽  
Gonzalo Perez-Arana ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Animal Model ◽  
Mass Loss ◽  
Autoimmune Diabetes ◽  
Cell Mass ◽  
Autoimmune Diabetes Mellitus

scholarly journals Non-autoimmune diabetes mellitus and the risk of virus infections: a systematic review and meta-analysis of case-control and cohort studies

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Eric Lontchi-Yimagou ◽  
Charly Feutseu ◽  
Sebastien Kenmoe ◽  
Alexandra Lindsey Djomkam Zune ◽  
Solange Fai Kinyuy Ekali ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Cohort Studies ◽  
H1n1 Virus ◽  
Autoimmune Diabetes ◽  
Meta Analysis ◽  
Case Control ◽  
Cochrane Central Register ◽  
Virus Infections ◽  
Autoimmune Diabetes Mellitus

AbstractA significant number of studies invoked diabetes as a risk factor for virus infections, but the issue remains controversial. We aimed to examine whether non-autoimmune diabetes mellitus enhances the risk of virus infections compared with the risk in healthy individuals without non-autoimmune diabetes mellitus. In this systematic review and meta-analysis, we assessed case-control and cohort studies on the association between non-autoimmune diabetes and viruses. We searched PubMed, Embase, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and Web of Science with no language restriction, to identify articles published until February 15, 2021. The main outcome assessment was the risk of virus infection in individuals with non-autoimmune diabetes. We used a random-effects model to pool individual studies and assessed heterogeneity (I2) using the χ2 test on Cochrane’s Q statistic. This study is registered with PROSPERO, number CRD42019134142. Out of 3136 articles identified, we included 68 articles (90 studies, as the number of virus and or diabetes phenotype varied between included articles). The summary OR between non-autoimmune diabetes and virus infections risk were, 10.8(95% CI: 10.3–11.4; 1-study) for SARS-CoV-2; 3.6(95%CI: 2.7–4.9, I2 = 91.7%; 43-studies) for HCV; 2.7(95% CI: 1.3–5.4, I2 = 89.9%, 8-studies;) for HHV8; 2.1(95% CI: 1.7–2.5; 1-study) for H1N1 virus; 1.6(95% CI: 1.2–2.13, I2 = 98.3%, 27-studies) for HBV; 1.5(95% CI: 1.1–2.0; 1-study) for HSV1; 3.5(95% CI: 0.6–18.3 , I2 = 83.9%, 5-studies) for CMV; 2.9(95% CI: 1–8.7, 1-study) for TTV; 2.6(95% CI: 0.7–9.1, 1-study) for Parvovirus B19; 0.7(95% CI: 0.3–1.5 , 1-study) for coxsackie B virus; and 0.2(95% CI: 0–6.2; 1-study) for HGV. Our findings suggest that, non-autoimmune diabetes is associated with increased susceptibility to viruses especially SARS-CoV-2, HCV, HHV8, H1N1 virus, HBV and HSV1. Thus, these viruses deserve more attention from diabetes health-care providers, researchers, policy makers, and stakeholders for improved detection, overall proper management, and efficient control of viruses in people with non-autoimmune diabetes.

scholarly journals Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management

2017 ◽  
Vol 10 (3) ◽  
pp. 897-909 ◽  
Author(s):  
Jonathan Kapke ◽  
Zachary Shaheen ◽  
Deepak Kilari ◽  
Paul Knudson ◽  
Stuart Wong
Keyword(s):  
Diabetes Mellitus ◽  
Monoclonal Antibody ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Immune Checkpoint ◽  
Autoimmune Diabetes ◽  
Human Monoclonal Antibody ◽  
Programmed Death ◽  
Autoimmune Diabetes Mellitus

With the introduction of immune checkpoint inhibitors into clinical practice, various autoimmune toxicities have been described. Antibodies targeting the receptor:ligand pairing of programmed death receptor-1 (PD-1) and its cognate ligand programmed death-ligand 1 (PD-L1) in rare reports have been associated with autoimmune diabetes mellitus. We report 2 cases of rapid-onset, insulin-dependent, type 1 diabetes mellitus in the setting of administration of nivolumab, a fully human monoclonal antibody to PD-1, and atezolizumab, a humanized monoclonal antibody to PD-L1. This appears to be the first report of autoimmune diabetes mellitus associated with atezolizumab. In addition, we provide a brief review of similar cases reported in the literature and a discussion of potential mechanisms for this phenomenon and propose a diagnostic and treatment algorithm.

Frequency and function of circulating invariant NKT cells in autoimmune diabetes mellitus and thyroid diseases in Colombian patients

2009 ◽  
Vol 70 (4) ◽  
pp. 262-268 ◽  
Author(s):  
Alejandro Roman-Gonzalez ◽  
Maria Eugenia Moreno ◽  
Juan Manuel Alfaro ◽  
Federico Uribe ◽  
Guillermo Latorre-Sierra ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Autoimmune Diabetes ◽  
Nkt Cells ◽  
Thyroid Diseases ◽  
Invariant Nkt Cells ◽  
And Function ◽  
Autoimmune Diabetes Mellitus
Sign in / Sign up

Export Citation Format

Share Document